Our core patent-pending technology is based on the acquisition and analysis of a very subtle pressure wave called a cardiogenic oscillation, measured from a patient’s airway. This signal is created every time our heart beats, when the right ventricle pumps blood into the pulmonary vasculature. By leveraging advances in sensors, cloud connectivity and computational approaches, we are turning this unique data stream into a groundbreaking modality for patient care management.
Our initial focus is for delivering a low-cost, non-invasive solution for effective management of congestive heart failure patients at home. To this end we have developed the Cardiospire, a small, portable and easy-to-use handheld device that easily and reliably acquires our unique data streams and transmits them to the cloud, where proprietary algorithms ascertain if a patient is approaching congestive heart failure decompensation before they experience symptoms, allowing their physician to guide medication to interdict traumatic and costly hospitalizations. Respirix has an opportunity to reduce more than $35 billion of annual costs associated with congestive heart failure hospitalizations in the U.S. alone, and estimated annual costs over $100 billion, with a solution that will be a win for patients, providers and payers.